William W. L. Wong

Dr. Wong’s research focuses on system-level policy modeling, infectious diseases modeling, health services and outcomes research, particularly in hepatitis B and C. His health services and outcomes research interests include quality of life research, costing and return on investment. Methodology research interests include advanced decision-analytic modeling techniques (such as discrete event simulation models and agent-based models) for health technology assessment, cost-effectiveness analysis, and pharmacoeconomics evaluation studies.

• Pharmacoeconomics

• Pharmacoinformatics

• health technology assessment

• Clinical Pharmacology

• Drug Discovery, Design and Delivery

Development of system-level policy models for hepatitis B virus (HBV), hepatitis C virus (HCV), and cardiovascular diseases (CVD)

Pharmacoeconomics of cancer therapies, and chronic hepatitis B/C therapies

Pharmacoinformatics: incorporating pharmacoeconomics model to enhance computational dru g discovery process

• 2012 Postdoctoral Fellowship Medical Decision Making and Health Economics, University of Toronto, Toronto, Ontario, Canada

• 2009 PhD Computer Science, University of Waterloo, Waterloo, Ontario, Canada

• 2000 MMath Computer Science, University of Waterloo, Waterloo, Ontario, Canada

• 1999 BSc Computer Science and Statistics, York University, Ontario, Canada

• 2023, Excellence in Science Research Award, Faculty of Science, University of Waterloo

• 2018-2023 Early Researcher Award, Ministry of Research, Innovation and Science, Government of Ontario

• Dr. Wong is a member of the Ontario Health Technology Advisory Committee (OHTAC) for Health Quality Ontario (HQO). He served as a health economics modeling expert for the province. The committee reviews health technology assessments and makes recommendations on which health care services and devices should be publicly funded.

• Dr. Wong is also a member of college of reviewers for CIHR.

• Since 2014, Dr. Wong has served as a modeling expert for various policy makers, including the Canadian Agency for Drugs and Technologies in Health (CADTH), the Public Health Agency of Canada (PHAC), and the Canadian Task Force on Preventive Health Care (CTPHC).

• PHARM 151 - Foundation and Application of Health Informatics
  • Taught in 2020, 2021, 2022
• PHARM 223 - Integrated Patient Focused Care 4
  • Taught in 2024
• PHARM 401 - Independent Study 2
  • Taught in 2021, 2022, 2023
• PHARM 618 - Applied Health Economics and Pharmacoeconomics
  • Taught in 2020, 2021, 2023, 2025

* Only courses taught in the past 5 years are displayed.

• Hirniak S, Edginton A, Iorio A, Wong W.W.L. (2025). A hemophilia joint health score-based model for the economic evaluation of hemophilia A prophylaxis interventions. PharmacoEconomics, v43:765-778.

• Saeed Y, Mitsakakis N, Feld J, Krahn M, Kwong J, Wong W.W.L. (2025) Health Utilities in People with Hepatitis C Virus Infection: A Study Using Real-world Population-level Data. Medical Decision Making, v45:3:332-343.

• Chayab L., Leighl N., Tadrous M., Warren C, Wong W.W.L. (2025). Trends in real-world clinical outcomes of patients with Anaplastic Lymphoma Kinase (ALK) rearranged non-Small Cell Lung Cancer (NSCLC) receiving one or more ALK Tyrosine Kinase Inhibitors (TKIs): a cohort study in Ontario, Canada. Current Oncology, v32:1:13

• Tian F, Forouzannia F, Feng Z, Biondi M, Mendlowitz A, Feld J, Sander B, Wong W.W.L. (2024). Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. Hepatology, v80:2:440-450

• Forouzannia F, Hamadeh A, Passos-Castilho AM, Erman A, Yu A, Feng Z, Janjua N, Sander B, Greenaway C, Wong W.W.L. (2024) Impact of new direct direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection in Canada, Liver International, v44:6:1383–1395

• Masucci L, Tian F, Tully S, Feng Z, McFarlane T, Chan KKW, Wong W.W.L. (2024). CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost–Utility Analysis. Medical Decision Making, v44:3:296–306

• Wong W.W.L., Wong J, Bremner B, Saeed Y, Mason K, Phoon A, Martel-Laferrière V, Bruneau J, Feld J, Feng Z, Baguley E, Lee S, Powis J, Krahn M. (2023) Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings. Liver International, v43:4:805-818.

• Wong W.W.L., Haines A, Wong J, Hamadeh A, Krahn M (2023). A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada. Scientific Report, v13:13484.

• Kim J., Alsbbagh W., Wong W.W.L. (2023). Cost-Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. PharmacoEconomics, v41:413-425.

• Wong W.W.L. Wong J, Bremner K, Saeed Y, Mason K, Phoon A, Feng Z, Feld J, Mitsakakis N, Powis J, Krahn M (2022). Time costs and out-of-pocket costs in chronic hepatitis C patients in a publicly funded health system. Value in Health, v25,2:247-256.

• Tian F, Feld J, Feng Z, Sander B, Wong W.W.L. (2022) Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. Journal of Hepatology, v77,4:947-956.

• Koo V, Tian F, Wong W.W.L. (2022). Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening. Liver International, v42,4:787-795.

• Wong W.W.L., Haines A, Bremner KE, Yao Z, Calzavara A, Mitsakakis N, Kwong J, Sander B, Thein H, Krahn M (2021). Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study, CMAJ Open, v9,1:E167-E174.

• Ellis K, Grindrod K, Tully S, McFarlane T, Chan KKW, Wong W.W.L. (2021). Understanding the feasibility of implementing CAR T-cell therapies from a Canadian perspective. Healthcare Policy, v16,3:89-105.

• Tian F, Houle S, Alsabbagh W, Wong W.W.L. (2020). Cost-effectiveness of Tenofovir Alafenamide for treatment of chronic hepatitis B in Canada. PharmacoEconomics, v38,2:181-192.

• Saeed Y, Phoon A, Bielecki JM, Mitsakakis N, Bremner K, Abrahamyan L, Pechlivanoglou P, Feld J, Krahn M, and Wong W.W.L. (2020) A Systematic Review and Meta-analysis of Health Utilities in Chronic Hepatitis C Patients, Value in Health, v23,1:127-137.

• For more on Dr. Wong's publications, see his Publications Webpage: http://www.williamwlwong.com/publications.html

• June 17, 2022: Ontario falls short in hep B prevention and screening, new study says
• January 15, 2015: Could a simple blood test combat Saskatchewan’s high rates of hepatitis C?